PTK2 and non-small cell lung carcinoma: As treatment with FAK TKI alone appeared to inhibit the viability of the EGFR TKI-resistant NSCLC cells tested in Fig 1, we next wanted to determine whether addition of PF-228 could sensitize cells to erlotinib, or at the very least, result in an additive reduction in cell viability above and beyond that of treatment with erlotinib alone.